Search Results - "Haupt, Axel"

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes by Thomas, Melissa K, Nikooienejad, Amir, Bray, Ross, Cui, Xuewei, Wilson, Jonathan, Duffin, Kevin, Milicevic, Zvonko, Haupt, Axel, Robins, Deborah A

“…Abstract Context Novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide…”
Get full text

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept by Coskun, Tamer, Urva, Shweta, Roell, William C., Qu, Hongchang, Loghin, Corina, Moyers, Julie S., O’Farrell, Libbey S., Briere, Daniel A., Sloop, Kyle W., Thomas, Melissa K., Pirro, Valentina, Wainscott, David B., Willard, Francis S., Abernathy, Matthew, Morford, LaRonda, Du, Yu, Benson, Charles, Gimeno, Ruth E., Haupt, Axel, Milicevic, Zvonko

“…With an increasing prevalence of obesity, there is a need for new therapies to improve body weight management and metabolic health. Multireceptor agonists in…”
Get full text

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept by Coskun, Tamer, Sloop, Kyle W., Loghin, Corina, Alsina-Fernandez, Jorge, Urva, Shweta, Bokvist, Krister B., Cui, Xuewei, Briere, Daniel A., Cabrera, Over, Roell, William C., Kuchibhotla, Uma, Moyers, Julie S., Benson, Charles T., Gimeno, Ruth E., D'Alessio, David A., Haupt, Axel

“…A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical…”
Get full text

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists by Urva, Shweta, Coskun, Tamer, Loghin, Corina, Cui, Xuewei, Beebe, Emily, O'Farrell, Libbey, Briere, Daniel A., Benson, Charles, Nauck, Michael A., Haupt, Axel

“…The effect of dual glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA) tirzepatide on gastric emptying…”
Get full text

Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk? by Schloot, Nanette C., Haupt, Axel, Schütt, Morten, Badenhoop, Klaus, Laimer, Markus, Nicolay, Claudia, Reaney, Matthew, Fink, Katharina, Holl, Reinhard W.

“…Background We investigated the rate of severe hypoglycemic events and confounding factors in patients with type 2 diabetes treated with sulfonylurea at…”
Get full text

New improved radiometabolite analysis method for [18F]FTHA from human plasma: a test-retest study with postprandial and fasting state by Aarnio, Richard, Kirjavainen, Anna, Rajander, Johan, Forsback, Sarita, Kalliokoski, Kari, Nuutila, Pirjo, Milicevic, Zvonko, Coskun, Tamer, Haupt, Axel, Laitinen, Iina, Haaparanta-Solin, Merja

“…Background Fatty acid uptake can be measured using PET and 14-( R,S )‐[ 18 F]fluoro‐6‐thia‐heptadecanoic acid ([ 18 F]FTHA). However, the relatively rapid rate…”
Get full text

Impact of Variation in the FTO Gene on Whole Body Fat Distribution, Ectopic Fat, and Weight Loss by Haupt, Axel, Thamer, Claus, Machann, Jürgen, Kirchhoff, Kerstin, Stefan, Norbert, Tschritter, Otto, Machicao, Fausto, Schick, Fritz, Häring, Hans‐Ulrich, Fritsche, Andreas

“…Polymorphisms in the fat mass‐ and obesity‐associated (FTO) gene have been identified to be associated with obesity and diabetes in large genome‐wide…”
Get full text

Association of obesity risk SNPs in PCSK1 with insulin sensitivity and proinsulin conversion by Heni, Martin, Haupt, Axel, Schäfer, Silke A, Ketterer, Caroline, Thamer, Claus, Machicao, Fausto, Stefan, Norbert, Staiger, Harald, Häring, Hans-Ulrich, Fritsche, Andreas

“…Prohormone convertase 1 is involved in maturation of peptides. Rare mutations in gene PCSK1, encoding this enzyme, cause childhood obesity and abnormal glucose…”
Get full text

Corannulenes with Electron‐Withdrawing Substituents: Synthetic Approaches and Resulting Structural and Electronic Properties by Haupt, Axel, Lentz, Dieter

“…Corannulene is a multifaceted polyaromatic compound. It has many interesting properties; for example, it has a bowl‐shaped molecular structure that, in…”
Get full text

An Obesity Risk SNP (rs17782313) near the MC4R Gene Is Associated with Cerebrocortical Insulin Resistance in Humans by Fritsche, Andreas, Häring, Hans-Ulrich, Tschritter, Otto, Machicao, Fausto, Sartorius, Tina, Hennige, Anita M., Haupt, Axel, Preissl, Hubert, Ketterer, Caroline

“…Activation of melanocortin-4 receptor (MC4R) by insulin sensitive neurons is a central mechanism in body weight regulation, and genetic variants in the MC4R…”
Get full text

Tuning the Electron Affinity and Stacking Properties of Corannulene by Introduction of Fluorinated Thioethers by Haupt, Axel, Lentz, Dieter

“…Trifluoromethylthio‐substituted corannulene can be easily synthesized in good yield by the reaction of iodocorannulene with CuSCF3. Oxidation with…”
Get full text

Integration of a LOHC storage into a heat-controlled CHP system by Haupt, Axel, Müller, Karsten

“…In order to enhance efficiency of thermal energy supply in residential buildings, combined heat and power (short: CHP) systems are more and more replacing…”
Get full text

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA by Rosenstock, Julio, Frias, Juan, Jastreboff, Ania M, Du, Yu, Lou, Jitong, Gurbuz, Sirel, Thomas, Melissa K, Hartman, Mark L, Haupt, Axel, Milicevic, Zvonko, Coskun, Tamer

“…According to current consensus guidelines for type 2 diabetes management, bodyweight management is as important as attaining glycaemic targets. Retatrutide, a…”
Get full text

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity by Wharton, Sean, Blevins, Thomas, Connery, Lisa, Rosenstock, Julio, Raha, Sohini, Liu, Rong, Ma, Xiaosu, Mather, Kieren J., Haupt, Axel, Robins, Deborah, Pratt, Edward, Kazda, Christof, Konig, Manige

“…In this 36-week, randomized trial, daily oral orforglipron was associated with weight reduction, with efficacy and safety similar to those of injectable GLP-1…”
Get full text

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial by Jastreboff, Ania M., Kaplan, Lee M., Frías, Juan P., Wu, Qiwei, Du, Yu, Gurbuz, Sirel, Coskun, Tamer, Haupt, Axel, Milicevic, Zvonko, Hartman, Mark L.

“…In this trial involving participants with obesity, 48 weeks of treatment with retatrutide, an agonist of the GIP, GLP-1, and GCG receptors, resulted in…”
Get full text

The Effect of Tirzepatide on Food Intake in Humans by Dunn, Julia, Haupt, Axel, Coskun, Tamer, Milicevic, Zvonko

“…Background: A dual GIP and GLP-1 receptor agonist (RA) tirzepatide delivered robust body weight (BW) loss in people with type 2 diabetes (T2D) and obesity in…”
Get full text

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes by Hartman, Mark L, Sanyal, Arun J, Loomba, Rohit, Wilson, Jonathan M, Nikooienejad, Amir, Bray, Ross, Karanikas, Chrisanthi A, Duffin, Kevin L, Robins, Deborah A, Haupt, Axel

“…To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of…”
Get full text

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial by Frias, Juan Pablo, Nauck, Michael A, Van, Joanna, Kutner, Mark E, Cui, Xuewei, Benson, Charles, Urva, Shweta, Gimeno, Ruth E, Milicevic, Zvonko, Robins, Deborah, Haupt, Axel

“…LY3298176 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for…”
Get full text

Association of obesity risk SNPs in PCSK1with insulin sensitivity and proinsulin conversion by Heni, Martin, Haupt, Axel, Schäfer, Silke A, Ketterer, Caroline, Thamer, Claus, Machicao, Fausto, Stefan, Norbert, Staiger, Harald, Häring, Hans-Ulrich, Fritsche, Andreas

“…Abstract Background Prohormone convertase 1 is involved in maturation of peptides. Rare mutations in gene PCSK1 , encoding this enzyme, cause childhood obesity…”
Get full text

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens by Frias, Juan Pablo, Nauck, Michael A., Van, Joanna, Benson, Charles, Bray, Ross, Cui, Xuewei, Milicevic, Zvonko, Urva, Shweta, Haupt, Axel, Robins, Deborah A.

“…Aim To assess the efficacy and tolerability of tirzepatide treatment using three different dose‐escalation regimens in patients with type 2 diabetes. Materials…”
Get full text